Fortrea announced plans to acquire Worldwide Clinical Trials’ early phase business unit. The transaction is valued at $45 million.
Further details about the acquisition were not immediately available.
Fortrea to acquire Worldwide’s early phase unit for $45 million
The deal expands Fortrea’s early-phase clinical research capabilities.
LF
Lucas Ferreira · Deals & Startups Desk · 2 Sept 2026 · 11:39 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
LF
Written by
Lucas Ferreira
Deals & Startups Desk
Lucas covers M&A activity and startup funding rounds, tracking deal structures and valuations to explain what a transaction means for the companies and markets involved.
More from Lucas Ferreira →
